论文部分内容阅读
应用亲和酶标组化标记法和免疫组化ＡＢＣ法，测定１０６例乳腺癌组织中ＥＲ、ＰＲ和ＤＡＫＯ—Ｍ１水平。其阳性率分别为８３％、８１．１％和８０．２％。在８８例ＥＲ阴性乳腺癌中，ＰＲ阳性７６例，而１８例ＥＲ阴性乳腺癌中，ＰＲ阳性１０例。７９．２％乳腺癌ＥＲ和ＰＲ表达一致（ｐ＜０．０５）。在９８例ＥＲ和／或ＰＲ阳性乳腺癌中，８４例ＤＡＫＯ—Ｍ１阳性；而８例ＥＲ和ＰＲ阴性乳腺癌中，７例ＤＡＫＯ—Ｍ１阴性。８５．７％乳腺癌ＥＲ和／或ＰＲ和ＤＡＫＯ—Ｍ１表达一致（Ｐ＜０．０５）。ＥＲ、ＰＲ和ＤＡＫＯ—Ｍ１阳性率均随组织学分级增高而减低，其在癌组织学分级表达中均有显著意义（ｐ＜０．０１—０．００１）。结果提示，乳腺癌ＥＲ、ＰＲ和ＤＡＫＯ—Ｍ１水平，均可作为对乳腺癌患者治疗方案决策、判断其分化程度和预测预后的参考指标。
The levels of ER, PR and DAKO-M1 in 106 cases of breast cancer were determined by affinity labeling and immunohistochemical ABC. The positive rates were 83%, 81.1% and 80.2%, respectively. In 88 cases of ER-negative breast cancer, PR-positive 76 cases, and 18 cases of ER-negative breast cancer, PR-positive in 10 cases. The expression of ER and PR was similar in 79.2% of breast cancers (p<0.05). Of the 98 cases of ER and/or PR positive breast cancer, 84 were DAKO-M1 positive; in 8 cases of ER and PR negative breast cancer, 7 were DAKO-M1 negative. 85.7% of breast cancers had the same expression of ER and/or PR and DAKO-M1 (P<0.05). The positive rates of ER, PR and DAKO-M1 decreased with increasing histological grading, and they had significant significance in the histological grade of cancer (p<0.01—0.001). The results suggest that the levels of ER, PR and DAKO-M1 in breast cancer can be used as reference indicators for the decision-making of breast cancer patients, judgment of their differentiation degree, and prognosis prediction.